Edward R. Ballister

The paper introduces NanoPro, a nanovector therapy platform using probiotically-released tumor-binding tags to target antigenically indistinct tumors, demonstrating in vitro efficacy with high transduction rates.

This paper develops a bacterial platform that combines enzyme/prodrug chemotherapy and immunotherapy to enhance antitumor responses with improved safety in a murine tumor model.

This study engineers probiotic E. coli to deliver neoantigen peptides, enhancing T cell immunity and reducing tumor growth in mice.

This study engineers a probiotic bacteria to selectively target pancreatic cancer, improving survival and modulating the tumor microenvironment.

This paper demonstrates that Lamplight, a bistable opsin, can be used for switchable and scalable optogenetic inhibition of neurons in mice.